Nifty Pharma appears to be resolving a multi-year consolidation within an ascending triangle, with price now testing a key supply zone near prior highs. The structure suggests accumulation over ~18–24 months, followed by a potential expansion phase.
This is not just a technical breakout attempt—sector fundamentals are turning supportive, driven by a shift toward high-margin specialty products, improving export visibility, and resilient domestic demand in chronic therapies.
A confirmed breakout could trigger both earnings momentum and valuation re-rating, positioning the index for a measured move toward the 27,000–28,000 zone over the medium term.
#HVF TheCryptoSniper
This is not just a technical breakout attempt—sector fundamentals are turning supportive, driven by a shift toward high-margin specialty products, improving export visibility, and resilient domestic demand in chronic therapies.
A confirmed breakout could trigger both earnings momentum and valuation re-rating, positioning the index for a measured move toward the 27,000–28,000 zone over the medium term.
#HVF TheCryptoSniper
Trade active
#Pharma is one of the strongest sectors in the #Indian market. As we are witnessing the index make new ATH's4000 points to go for the Log 3 tgt
Note
#SUNPHARMANote
pharma index takes a breather when there is a risk on sentiment...Note
#Pharma is relentlesseven with Traiff drama
T3's in sight now...
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.